Pharmacists’ Shifting Meeting Preferences

Article

Pharmacists’ Shifting Meeting Preferences

April 20, 2023
Authors
Topics

Welcome to the April 2023 edition of our Monthly Insight Series. This month we are evaluating the desire among oncology pharmacists to return to in-person meetings.

Business Meeting

We have begun analyzing our preliminary 2023 Integrated Delivery Network (IDN) survey data and have found that oncology pharmacists are once again looking forward to meeting manufacturer team members in person. Our 2022 research found providers still grappling with COVID-19 impacts and preferring virtual meetings. Now, with a better understanding of COVID and its effects, providers’ preferences are shifting toward in-person interactions, although virtual options remain in the mix. 

Source: HMP Market Access Insights.
Abbreviations: HCP, health care professional.

We are now conducting our follow-up interviews, and beyond the survey findings the oncology pharmacists tell us:

  • Independent web and health care professional site searches remain their most flexible option to obtain clinical or drug administration information.
  • Virtual meetings with pharmaceutical personnel provide efficient interactions that are more accommodating for clinic schedules.
  • In-person meetings (on site or at conferences) offer greater opportunities for the pharmacy staff/team to build relationships with manufacturer personnel and experience interactive learning sessions.

Stay tuned for more insights and the publication of our 2023 IDN Oncology Trend Survey next month.  Until then, please reach out with any comments or questions you may have.

The Latest

Revolutionizing Cancer Care: EOM's Second Wind and its Current Impact on Community Oncology Practices

The second Enhancing Oncology Model (EOM) application cycle closed on September 16, signaling shifts in community oncology. Explore our 2024 Community Oncology Report to understand EOM’s current impact and changes from this round.

Ashutosh Sheth
Key takeaways from CPC+CBEx 2024
Article
Bispecific Therapies in Community Oncology: Bridging Insights from CPC+CBEx and Beyond

Explore key takeaways from CPC+CBEx on bispecific therapies, highlighting collaboration between hospitals and community practices to expand access and tackle financial challenges.

Daniel Buchenberger
Figure 1: Community Oncology Actions to Address Any Potential Impact of the IRA   Source: HMP Market Access Insights 2024 Community, and Payer Oncology Trend Report.
Article
Community Oncology: Awareness v Action in the Face of the IRA

The Inflation Reduction Act (IRA) will significantly impact community oncology practice financials. As we approach this shift, our latest research from the 2024 Community Oncology Report reveals a current gap between awareness and action.

Emma Bijesse